Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

181. Entering menopause increases the risk of first episode depression

Entering menopause increases the risk of first episode depression Entering menopause increases the risk of first episode depression | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Entering menopause increases the risk of first episode depression Article Text Aetiology Entering menopause increases the risk of first episode depression Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article

2006 Evidence-Based Mental Health

182. Canadian Consensus Conference on Menopause, 2006 Update

Canadian Consensus Conference on Menopause, 2006 Update Canadian Consensus Conference on Menopause, 2006 Update - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 28, Issue 2, Supplement, Pages S7–S9 Canadian Consensus Conference on Menopause, 2006 Update CONFERENCE CHAIRS, x Serge Bélisle , MD, MSc, FRCSC Montreal QC x Jennifer Blake , MD, MSc, FRCSC Toronto ON x MENOPAUSE GUIDELINES COMMITTEE x Rosemary Basson , MD (...) Senikas , x Michele Turek , MD, FRCPC x Michele Turek PROJECT COORDINATOR, x Elke Henneberg Communications Message & More Inc, Sutton QC TRANSLATION, x Martin Pothier , B.Sc. SOGC x Chantal Capistran , hons. B.A. SOGC DOCUMENT MANAGEMENT, x Jackie Oman SOGC DOI: ABSTRACT Objective To provide guidelines for health care providers on the management of menopause in asymptomatic healthy women as well as in women presenting with vasomotor symptoms, urogenital, sexual, and mood and memory concerns

2006 Society of Obstetricians and Gynaecologists of Canada

183. Depression increases in women during early to late menopause but decreases after menopause Full Text available with Trip Pro

Depression increases in women during early to late menopause but decreases after menopause Depression increases in women during early to late menopause but decreases after menopause | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Depression increases in women during early to late menopause but decreases after menopause Article Text Aetiology Depression increases in women during early to late menopause but decreases after menopause Free Hayden B

2005 Evidence-Based Mental Health

184. Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women Full Text available with Trip Pro

Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Paroxetine controlled release was effective and tolerable for treating menopausal hot flash symptoms in women Article Text Therapeutics Paroxetine controlled release

2005 Evidence-Based Medicine

185. Does scientific evidence support the use of non-prescription supplements for treatment of acute menopausal symptoms such as hot flushes?

Does scientific evidence support the use of non-prescription supplements for treatment of acute menopausal symptoms such as hot flushes? Does scientific evidence support the use of non-prescription supplements for treatment of acute menopausal symptoms such as hot flushes? Does scientific evidence support the use of non-prescription supplements for treatment of acute menopausal symptoms such as hot flushes? Hanna K, Day A, O'Neill S, Patterson C, Lyons-Wall P CRD summary This review assessed (...) non-prescription supplements for menopausal symptoms, particularly hot flushes. The authors concluded that the limited evidence about red clover, soy, sage and black cohosh suggests that more research is required. Given the limitations of the review and the paucity of evidence for some interventions, the authors' conservative conclusions and suggestions for further research seem appropriate. Authors' objectives To evaluate non-prescription supplements (NPS) for the treatment of menopausal symptoms

2005 DARE.

186. Management of menopause-related symptoms

Management of menopause-related symptoms Management of menopause-related symptoms Management of menopause-related symptoms Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C, Vesco K, Walker M, Bougatsos C, Nygren P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis (...) C, Vesco K, Walker M, Bougatsos C, Nygren P. Management of menopause-related symptoms. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 120. 2005 Authors' objectives This report aims to describe the evidence about symptoms associated with menopause, factors that influence them, benefits and adverse effects of therapies, factors that influence therapies, and future research needs. Authors' conclusions Vasomotor symptoms and vaginal dryness

2005 Health Technology Assessment (HTA) Database.

187. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials

Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

188. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy

Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy Schousboe J T, Ensrud K E (...) . Source of funding Supported by Hologic Inc., Pfizer Inc., and Eli Lilly and Co. Bibliographic details Schousboe J T, Ensrud K E, Nyman J A, Kane R L, Melton L J. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis International 2005; 16(12): 1883-1893 PubMedID DOI Other publications of related interest Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal

2005 NHS Economic Evaluation Database.

189. Treatment of menopausal symptoms: what shall we do now? (Abstract)

Treatment of menopausal symptoms: what shall we do now? During the past few years, many women and doctors have revised their opinions of hormone replacement therapy (HRT) for menopausal symptoms, and a substantial number of individuals have discontinued its use because of concerns about side-effects. Numerous alternatives to HRT are promoted, and assessment of the quality of evidence about the safety and effectiveness of these compounds can be difficult. In this Review, we summarise the data (...) from studies addressing the efficacy, risks, and benefits of frequently prescribed treatments, and offer evidence-based clinical guidelines for the management of menopausal symptoms. Although few comparative studies exist, oestrogen alone or combinations of oestrogen and progestagen are likely to be the most effective treatments for menopausal hot flushes and vaginal dryness. Tibolone is as effective as HRT, however, and might also improve libido. For those who wish to avoid hormonal treatments

2005 Lancet

190. Menopause and hypothalamic-pituitary sensitivity to estrogen. Full Text available with Trip Pro

Menopause and hypothalamic-pituitary sensitivity to estrogen. The onset of human menopause is thought to be caused solely by ovarian failure and oocyte depletion. However, clinical symptoms and certain recent data in perimenopausal women suggest central nervous system involvement.To determine if modifications of hypothalamic-pituitary response to estrogen feedback mechanisms occur in older reproductive-age women as a mechanism of the onset of menopause.The Study of Women's Health Across (...) the Nation (SWAN) is a multiethnic observational cohort study of the menopausal transition in 3302 women at 7 US sites. Of the subcohort of 840 women who participated in the Daily Hormone Study between 1997 and 1999, 680 women had evidence of luteal activity. The remaining 160 women (19%) did not have luteal activity and are the subject of this report.Daily urinary hormone levels of estrogen and progesterone metabolites, luteinizing hormone (LH), and follicle-stimulating hormone (FSH).Three groups

2004 JAMA

191. Oestrogen plus progestin doubles the risk of dementia in post-menopausal women Full Text available with Trip Pro

Oestrogen plus progestin doubles the risk of dementia in post-menopausal women Oestrogen plus progestin doubles the risk of dementia in post-menopausal women | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oestrogen plus progestin doubles the risk of dementia in post-menopausal women Article Text Therapeutics Oestrogen plus progestin doubles the risk of dementia in post-menopausal women Free Barbara B Sherwin , PhD , Professor , James

2004 Evidence-Based Mental Health

192. Review: most herbal treatments have no benefit for menopausal symptoms Full Text available with Trip Pro

Review: most herbal treatments have no benefit for menopausal symptoms Review: most herbal treatments have no benefit for menopausal symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: most herbal treatments have no benefit for menopausal symptoms Article Text Therapeutics Review: most herbal treatments have no benefit for menopausal symptoms Free Angela M Cheung , MD, PhD , Rishma Walji , BSc, ND Statistics from

2004 Evidence-Based Medicine

193. Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status

Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status Critchley H O D, Warner P, Lee A J, Brechin S, Guise J, Graham B Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Critchley H O D, Warner P, Lee A J, Brechin S, Guise J, Graham B. Evaluation of abnormal uterine bleeding: comparison of three outpatient procedures within cohorts defined by age and menopausal status. Health Technology Assessment 2004; 8(34): 1-154 Authors' objectives This study aimed to compare three outpatient methods

2004 Health Technology Assessment (HTA) Database.

194. Phytoestrogens for treatment of menopausal symptoms: a systematic review

Phytoestrogens for treatment of menopausal symptoms: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

195. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. (Abstract)

Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA. Mitochondrial dysfunction is also suspected to participate in the pathogenesis of Parkinson's (...) emission tomography (PET).We recorded mutations in POLG in members of all seven families. Clinical assessment showed significant cosegregation of parkinsonism with POLG mutations (p<0.0001), and PET findings were consistent with dopaminergic neuron loss. Post-mortem examination in two individuals showed loss of pigmented neurons and pigment phagocytosis in substantia nigra without Lewy bodies. Furthermore, most women with progressive external ophthalmoplegia had early menopause-before age 35 years

2004 Lancet

196. Bone loss and bone size after menopause. Full Text available with Trip Pro

Bone loss and bone size after menopause. Bone loss increases after menopause. However, bone strength also depends on structural characteristics such as bone size. Whether bone size increases as a result of periosteal apposition and whether a strength index accounting for both bone density and bone size might predict the risk of fracture better than bone density alone are unclear.Bone mass and the skeletal structure of the distal radius were evaluated by single-photon absorptiometry every other (...) year in 108 women, all of whom were followed from the time of menopause for a mean period of 15 years. Postmenopausal serum estradiol levels and fractures of the distal radius were noted.The mean (+/-SD) annual decrease in bone mineral density was 1.9+/-0.7 percent. The medullary bone diameter increased annually by 1.1+/-0.9 percent, and the periosteal diameter by 0.7+/-0.3 percent; the strength index decreased by 0.7+/-0.7 percent. The expansion of the medullary diameter and the expansion

2003 NEJM

197. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. Full Text available with Trip Pro

Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective.To evaluate a selective serotonin reuptake inhibitor (paroxetine controlled release [CR]) in treating the vasomotor symptoms displayed by a general cross-section of menopausal women.Randomized (...) , double-blind, placebo-controlled, parallel group study conducted across 17 US sites, including urban, suburban, and rural clinics.A total of 165 menopausal women aged 18 years or older experiencing at least 2 to 3 daily hot flashes and must have discontinued any hormone replacement therapy for at least 6 weeks. Women were excluded if they had any signs of active cancer or were undergoing chemotherapy or radiation therapy.After a 1-week placebo run-in phase, study participants were randomized

2003 JAMA Controlled trial quality: predicted high

198. A systematic review of herbal medicinal products for the treatment of menopausal symptoms

A systematic review of herbal medicinal products for the treatment of menopausal symptoms Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

199. Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis

Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis Doren M, Nilsson J A, Johnell O CRD summary This review assessed the effects of hormone therapy on bone mineral density in postmenopausal (...) acetate, levonorgestrel, cyproterone acetate, norethisterone (norethindrone) acetate, desogestrel and norgestrel. Participants included in the review Studies in postmenopausal and/or ovariectomised women were eligible for inclusion, regardless of prior fracture history. The classification of women as postmenopausal in the primary studies was accepted. Most of the women in the included studies were aged 50 to 60 years (range: 40 to 76). Most studies were conducted in early-menopausal women with both

2003 DARE.

200. Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief Full Text available with Trip Pro

Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief Dog T L, Powell K L, Weisman S M CRD summary This review concluded that extracts of Cimifuga are safe to use in women with menopausal symptoms. The conclusion was generally in line with the evidence presented. The review had methodological (...) and reporting weaknesses that make it difficult to be certain of the reliability of the conclusions. Authors' objectives To assess the safety of Cimicifuga racemosa in women with menopausal symptoms. Searching MEDLINE, EMBASE, BIOSIS Previews and SciSearch were searched. Searches were also conducted of the Food and Drug Administration (FDA) and World Health Organization (WHO) adverse event reporting systems, monographs, compendia, and unpublished data from Schnaper and Brummer. The search terms for the FDA

2003 DARE.